Navigation Links
Insights gained from growing cold-causing virus on sinus tissue
Date:4/10/2011

MADISON - Using sinus tissue removed during surgery at University of Wisconsin Hospital and Clinics, researchers at the University of Wisconsin-Madison have managed to grow a recently discovered species of human rhinovirus (HRV), the most frequent cause of the common cold, in culture.

The researchers found that the virus, which is associated with up to half of all HRV infections in children, has reproductive properties that differ from those of other members of the HRV family.

The accomplishments, reported in Nature Medicine on April 11, should allow antiviral compounds to be screened to see if they stop the virus from growing.

The report sheds light on HRV-C, a new member of the HRV family that also includes the well-known HRV-A and HRV-B. Discovered five years ago, HRV-C has been notoriously difficult to grow in standard cell cultures and, therefore, impossible to study.

"We now have evidence that there may be new approaches to treating or preventing HRV-C infections," says senior author James Gern, professor of medicine at the UW-Madison School of Medicine and Public Health and an asthma expert at American Family Children's Hospital.

Future drugs could be especially useful for children and adults who have asthma and other lung problems, Gern says.

Recent studies have shown that in addition to its major role in the common cold, HRV-C is responsible for between 50 percent and 80 percent of asthma attacks. HRV-C is a frequent cause of wheezing illnesses in infants and may be especially likely to cause asthma attacks in children. HRV infections of all kinds also can greatly worsen chronic lung diseases such as cystic fibrosis and chronic obstructive pulmonary disease.

Like other scientists, Yury Bochkov, a virologist in Gern's lab, was unable to grow HRV-C in standard cell lines. So he turned to nasal tissue he collected following sinus surgeryand was surprised to find success. He grew significa
'/>"/>

Contact: Toni Morrissey
tmorrissey@uwhealth.org
608-263-3223
University of Wisconsin-Madison
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Bird embryo provides unique insights into development related to cancer and wound healing
2. New insights into cancer treatment
3. Scientists reveal new insights into tendon injury
4. First Look at Prostate Cancer Genome Yields Insights
5. New Insights on Who Should Take Erbitux for Colon Cancer
6. Sodium MRI gives new insights into detecting osteoarthritis, NYU researchers find
7. Snake venom studies yield insights for development of therapies for heart disease and cancer
8. Cell symposia meeting, Influenza: Translating basic insights, to be held Dec. 2-4, 2010
9. From head to toe: Deep insights from whole body MRI
10. Emerald Express International to be Featured on ‘Insights' with Hugh Downs this Spring in a Segment that Spotlights Glutathione and Anti-Aging
11. Expert Insights on Health Data Sharing, Collaboration, Quality and Meaningful Use Featured in Latest Carefx Position Paper
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... Medical Ministry International announced today that ... by GreatNonprofits , the leading provider of user reviews ... a Top-Rated 2013 Nonprofit,” says Samuel Smith, MMI CEO. ... 3000 Volunteers and Staff serving in 22 countries around the ... those that have seen our work first hand and wanted ...
(Date:5/21/2013)... on a large scale is the cornerstone of ... better outcomes, better value and better experience of ... patient-centered medical home model offers a viable solution ... of Health and Human Services, Agency for Healthcare ... more about the processes and determinants of successful ...
(Date:5/21/2013)... NC (PRWEB) May 21, 2013 Mecklenburg ... Charlotte will hold a free Community Wellness Fair to ... The fair will be held on Wednesday, May 22, ... University City YMCA (8100 Old Mallard Creek Road, Charlotte, ... American Heart Association and the Mecklenburg County Department ...
(Date:5/21/2013)... 2013, Paris, France: The Orsiro stent, which is ... biodegradable polymer, demonstrated non-inferiority to the Xience Prime ... in-stent late lumen loss at nine months in ... EuroPCR 2013 today. , The BIOFLOW-II substudy used ... to quantitatively assess neointimal hyperplasia and stent apposition ...
(Date:5/21/2013)... 2013 The In View series ... and cable channels across the country, announces it has ... channel. The producers of the series proudly bring audiences ... industry, the manufacturing industry, health-related companies, medical facilities and ... medical practitioners in all parts of the United States, ...
Breaking Medicine News(10 mins):Health News:Medical Ministry International Recognized as a 2013 Top-rated Nonprofit By GreatNonprofits.org 2Health News:AHRQ-funded journal supplement offers lessons on primary care practice transformation 2Health News:AHRQ-funded journal supplement offers lessons on primary care practice transformation 3Health News:AHRQ-funded journal supplement offers lessons on primary care practice transformation 4Health News:AHRQ-funded journal supplement offers lessons on primary care practice transformation 5Health News:AHRQ-funded journal supplement offers lessons on primary care practice transformation 6Health News:Mecklenburg EMS Agency Teams Up with the YMCA of Greater Charlotte and Others to Educate the Public on Health Related Initiatives 2Health News:Biodegradable stent proves non-inferior to drug-eluting stent 2Health News:In View hosted by Larry King Announces New Videos on its YouTube Channel 2
... Tobacco-Free,Kids, WASHINGTON, Oct. 2 The following is ... Kids:, The Campaign for Tobacco-Free Kids applauds Tyra ... exposing the ugly truth that,smoking is not only dangerous ... week,s season premiere of "America,s Next Top Model",featured a ...
... Manchester scientists will discuss their research aimed at reducing ... at the National Cancer Research Institute conference in Birmingham ... patients receive radiotherapy as part of their cancer treatment ... causing side effects (toxicity) to the normal tissues and ...
... For the first time, data show a positive ... overall health at birth. Babies born to women with ... to be less likely to need intensive care than ... Inc. (NASDAQ:CBRX) announced today. The data are published in ...
... Angel Flight West (AFW),awarded The Distinguished Pilot award ... Awards on Saturday, September 29. Dr. Irish,completed 18 Angel ... AFW,pilot, he flies people in need whose non-emergency health ... facilities. Dr. Irish, like,all AFW volunteer pilots, donates the ...
... Does your October purchase really make a difference?, ... products to,benefit the breast cancer cause, Y-ME National Breast ... make meaningful,consumer choices to ensure that their money really ... consumers can take to become informed about,pink, promotions so ...
... HILL, N.C., Oct. 2 The U.S. hospital ... vying to get their,therapies on hospital formularies. Among ... time with key physicians and the list of ... companies are working their way into formularies via,specialized ...
Cached Medicine News:Health News:Tobacco-Free Kids Applauds Tyra Banks for Exposing the Ugly Truth About Smoking 2Health News:Cancer researchers seek safe reduction of radiotherapy 2Health News:Vaginal progesterone gel may improve infant outcomes and... 2Health News:Vaginal progesterone gel may improve infant outcomes and... 3Health News:Vaginal progesterone gel may improve infant outcomes and... 4Health News:Angel Flight West Recognizes Colorado Pilots and Supporters at AFW 24th Anniversary Awards 2Health News:National Breast Cancer Awareness Month 2Health News:Equipping your Sales Force to Influence Hospital Formulary Decision-Makers 2
(Date:5/21/2013)... , May 21, 2013  Vasomedical, Inc. (OTC BB: ... the design, manufacture and sale of medical devices and in ... Dr. Jun Ma , President and CEO ... LLP MicroCap Conference on Thursday, May 30, 2013 in ... Hotel. The Company,s presentation is scheduled to ...
(Date:5/21/2013)... 21, 2013 Reportlinker.com announces that ... in its catalogue:   ... Optical Coherence Tomography (OCT) ... OBJECTIVES   BCC,s ... offer synopsis of the current and future ...
(Date:5/21/2013)... Fla. , May 21, 2013  Janssen ... safety results from the global Phase 3 PROMISE ... inhibitor simeprevir (TMC435) led to sustained virologic response ... in 79 percent of treatment-experienced genotype 1 chronic ... including all stages of liver fibrosis, when administered ...
Breaking Medicine Technology:Vasomedical, Inc. To Present At The Second Annual Marcum LLP MicroCap Conference 2Global Markets and Technologies for Optical Coherence Tomography (OCT) 2Global Markets and Technologies for Optical Coherence Tomography (OCT) 3Global Markets and Technologies for Optical Coherence Tomography (OCT) 4Global Markets and Technologies for Optical Coherence Tomography (OCT) 5Global Markets and Technologies for Optical Coherence Tomography (OCT) 6Global Markets and Technologies for Optical Coherence Tomography (OCT) 7Global Markets and Technologies for Optical Coherence Tomography (OCT) 8Global Markets and Technologies for Optical Coherence Tomography (OCT) 9Global Markets and Technologies for Optical Coherence Tomography (OCT) 10Global Markets and Technologies for Optical Coherence Tomography (OCT) 11Global Markets and Technologies for Optical Coherence Tomography (OCT) 12Global Markets and Technologies for Optical Coherence Tomography (OCT) 13Global Markets and Technologies for Optical Coherence Tomography (OCT) 14Global Markets and Technologies for Optical Coherence Tomography (OCT) 15Global Markets and Technologies for Optical Coherence Tomography (OCT) 16Global Markets and Technologies for Optical Coherence Tomography (OCT) 17Global Markets and Technologies for Optical Coherence Tomography (OCT) 18Global Markets and Technologies for Optical Coherence Tomography (OCT) 19Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 2Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 4Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 5Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 6Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 7
... ... Release Formulation, CHICAGO, April ... sustained-release investigational compound to treat,Restless Legs Syndrome (RLS), showed that ... placebo, and was,generally well-tolerated when administered once-daily for 12 weeks., ...
... Expansion of Company,s Phase 3 Study for Wet AMD after ... 90-day Review ... announced,today that the U.S. Food and Drug Administration (FDA) has granted ... Phase 3 trial from 10 to 30 in the United States. ...
Cached Medicine Technology:Data Presented at the American Academy of Neurology Show XP13512/GSK1838262 Significantly Improved Symptoms of Moderate-to-Severe Primary Restless Legs Syndrome 2Data Presented at the American Academy of Neurology Show XP13512/GSK1838262 Significantly Improved Symptoms of Moderate-to-Severe Primary Restless Legs Syndrome 3Data Presented at the American Academy of Neurology Show XP13512/GSK1838262 Significantly Improved Symptoms of Moderate-to-Severe Primary Restless Legs Syndrome 4Data Presented at the American Academy of Neurology Show XP13512/GSK1838262 Significantly Improved Symptoms of Moderate-to-Severe Primary Restless Legs Syndrome 5Data Presented at the American Academy of Neurology Show XP13512/GSK1838262 Significantly Improved Symptoms of Moderate-to-Severe Primary Restless Legs Syndrome 6FDA Grants NeoVista's Request to Expand CABERNET Trial to 30 Sites in the U.S. 2FDA Grants NeoVista's Request to Expand CABERNET Trial to 30 Sites in the U.S. 3
Round, height-adjustable, steel laboratory stools with small footprint for small spaces • Choose options like different height-adjustment mechanism or paint finish. • your choice of color...
... panels mounted on powder-coated steel ... free-standing modular cleanroom that meets ... Optional ceiling HEPA filter/fan units, ... to customer requirements. Negative-pressure ventilation, ...
... ideal modular cleanroom for biological safety ... require cleanliness (to Class 10/ISO 3) ... to create ultra-smooth surfaces that are ... One-inch radius corners simplify cleaning. Unique ...
Inquire...
Medicine Products: